Hitachi Chemical Licenses Cell Culture Media and Methods from Accellta Ltd.
Robert A. Preti, PhD, Chief Executive Officer and President, Hitachi Chemical Advanced Therapeutics Solutions | February 6, 2018
On February 5, 2018, Hitachi Chemical Co., Ltd., parent company of Hitachi Chemical Advanced Therapeutics Solutions, LLC, issued the exciting news that the parent company has licensed stem cell culture media and methods from Accellta Ltd, an Israel-based firm offering a range of innovative proprietary technology designed to offer high quality, affordable cell culturing solutions.
The Accellta technology may offer interesting advantages, including a high level of safety and the enabling of larger scale cell culturing compared to standard cell suspension cultures.
In the case that clients and followers of PCT services may have missed this announcement, I wanted to highlight it—including the following quote:
“With the Technology License Agreement signed with Accellta and the utilization of licensed technologies regarding Accellta’s stem cell culture media and culture methods, Hitachi Chemical now seeks to reinforce its technological strength in contracted cell manufacturing for regenerative medicine to achieve high quality, low-priced cell production. Looking ahead, Hitachi Chemical plans to customize culture media to match the products developed by pharmaceutical companies or other customers, offering added value to clients of the PCT regenerative medicine contract development and manufacturing services platform looking for integrated solutions. In addition to culture media, Hitachi Chemical also plans to take full advantage of its accumulated knowledge in the materials technology field to engage in the manufacture of expendable supplies, such as containers and reagents, and will accelerate the expansion of businesses related to regenerative medicine even further.”
This business expansion, and others like it that may come in the future, should serve to grow the business of Hitachi Chemical as well as increase the value proposition for PCT services directly. We will keep our clients apprised of future developments as this technology is evaluated and potentially integrated into our service offerings.
Robert A. Preti, PhD, Chief Executive Officer and President, Hitachi Chemical Advanced Therapeutics SolutionsRobert “Bob” Preti is the co-founder of Hitachi Chemical Advanced Therapeutics Solutions ("HCATS", formerly PCT) and the visionary behind its successful growth and development strategy over much of the last two decades.
Subscribe to our blog for instant updates on challenges and trends in cell therapy development, manufacturing and commercialization.